ADC Therapeutics reported steady net product revenues of $15.8 million in Q3 2025, reflecting consistent demand for its lead product, ZENLATA, while positioning for future growth through ongoing clinical trials and recent financing.

• Net product revenues were stable, matching quarterly run rates from the previous two years.
• Secured a $60 million private placement, extending the cash runway into 2028.
• Multiple ongoing clinical trials for ZENLATA are expected to bolster its market position, with potential expansions into earlier treatment lines and additional lymphoma types.
• Anticipation for upcoming data releases from key trials, including LOTUS V and LOTUS seven, which could enhance revenue projections significantly.
• Long-term peak annual revenue for ZENLATA is estimated between $600 million and $1 billion, contingent on successful trial outcomes and market expansion.